Patient-reported outcomes in individuals with hepatitis C virus infection treated with elbasvir/grazoprevir
Xinyi Ng,1 Chizoba Nwankwo,2 Jean Marie Arduino,2 Shelby Corman,1 Kathryn Eilene Lasch,1 Jacqueline Mary Lustrino,1 Sushma Patel,2 Heather Loryn Platt,2 Jingjun Qiu,2 Jan Sperl3 1Pharmerit International, LP, Bethesda, MD, USA; 2Merck & Co. Inc., Kenilworth, NJ, USA; 3Department of Hepatogas...
Main Authors: | Ng X, Nwankwo C, Arduino JM, Corman S, Lasch KE, Lustrino JM, Patel S, Platt HL, Qiu J, Sperl J |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2018-12-01
|
Series: | Patient Preference and Adherence |
Subjects: | |
Online Access: | https://www.dovepress.com/patient-reported-outcomes-in-individuals-with-hepatitis-c-virus-infect-peer-reviewed-article-PPA |
Similar Items
-
Limited drug–drug interaction of elbasvir/grazoprevir for chronic hepatitis C
by: Chun-Jen Liu, et al.
Published: (2020-05-01) -
Spotlight on grazoprevir—elbasvir once-daily combination and its potential in the treatment of hepatitis C
by: Suraweera D, et al.
Published: (2016-06-01) -
Elbasvir/Grazoprevir, an Alternative in Antiviral Hepatitis C Therapy in Patients under Amiodarone Treatment
by: Lina Weiss, et al.
Published: (2018-02-01) -
An integrated analysis of elbasvir/grazoprevir in Korean patients with hepatitis C virus genotype 1b infection
by: Youn Jae Lee, et al.
Published: (2019-12-01) -
Effectiveness and safety of elbasvir/grazoprevir in Korean patients with hepatitis C virus infection: a nationwide real-world study
by: Eun Sun Jang, et al.
Published: (2021-03-01)